Researchers at the Max Perutz Labs, a joint venture of the Medical University of Vienna and the University of Vienna, have succeeded in unlocking how a cellular drug transporter drives MDR. The results suggest new therapeutic strategies to prevent MDR in the case of cancer therapy or infections.
For this purpose, the researchers applied an interdisciplinary approach in which the predictions of computational models were confirmed by experimental genetic alterations.
About the Max Perutz Labs
The Max Perutz Labs are a research institute established by the University of Vienna and the Medical University of Vienna. The institute carries out excellent, internationally recognised research and education in the field of molecular biology. Dedicated to carrying out research to gain a mechanistic understanding of fundamental biomedical processes, scientists at the Max Perutz Labs aim to link breakthroughs in basic research to medically relevant issues. The Max Perutz Labs are located at the Vienna BioCenter, one of Europe's leading hotspots for life sciences. The labs host around 50 research groups, involving more than 450 scientists and staff from 40 nations. www.maxperutzlabs.ac.at
Read about the blog on the issue of cancer research in Austria: successfully linked research and practice.